臨床婦人科産科71巻1号

2017年01月発行

合併増大号　今月の臨床 性ステロイドホルモン研究の最前線と臨床応用

選択的性ステロイドホルモン受容体修飾薬

選択的アンドロゲン受容体修飾薬（SARM）

著者： 柳瀬敏彦¹

所属機関： ¹福岡大学医学部内分泌・糖尿病内科

ページ範囲：P.127 - P.132

文献概要

●近年，骨や筋肉には有益なアンドロゲンのアナボリックな作用を保持したまま，アンドロゲンの好ましくない作用である前立腺刺激作用は発揮させないような薬剤，いわゆるSARMの研究開発が進みつつある．

●骨粗鬆症や加齢性筋肉減少症（サルコペニア）を主な治療標的とするSARMの研究開発が主流となっているが，現時点で市場に出ているものは皆無である．

●最近，がんに伴うカヘキシア（悪液質）患者を対象にしたSARM投与の有効性が報告されている．

参考文献

1）Bhasin S, et al : Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12 : 232─240, 2009

2）古屋和行 : 骨選択的アンドロゲン受容体調節剤．Clin Calcium 20 : 225─233, 2010

3）Forbes GB, et al : Adult lean body mass declines with age : some longitudinal observations. Metabolism 19 : 653─663, 1970

4）Roy TA, et al : Interrelationships of serum testosterone and free testosterone and index with FFM and strength in aging men. Am J Physiol Endocrinol Metab 283 : E284─E294, 2002

5）Ottenbacher KJ, et al : Androgen treatment and muscle strength in elderly males : a meta-anlysis. J Am Geriatr Soc 54 : 1666─1673, 2006

6）Sinha-Hikim I, et al : Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 283 : E154─E164, 2002

7）Hawke TJ, et al : Myogenic satellite cells : physiology to molecular biology. J Appl Physiol 91 : 534─551, 2001

8）Singh R, et al : Regulation of myogenic differentiation by androgens : cross-talk between androgen receptor/β-catenin and follistatin/TGF-β signaling pathways. Endocrinology 150 : 1259─1268, 2009

9）Jones A, et al : Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 151 : 3706─3719, 2010

10）Kovacheva EL, et al : Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 151 : 628─638, 2010

11）Mendler L, et al : Androgens negatively regulate myostatin expression in an androgen-dependent skeletal muscle. Biochem Biophys Res Commun 361 : 237─242, 2007

12）Min L, et al : A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate. Endocrinology 150 : 5606─5616, 2009

13）蘆田健二，他 : アンドロゲンの骨への作用．Clin Calcium 20 : 165─173, 2010

14）Page ST, et al : Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats : selective stimulation of muscle mass and bone mineral density relative to prostate mass. Endocrinology 149 : 1987─1993, 2008

15）Smith CL, et al : Coregulator function : a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 : 45─71, 2004

16）Shang Y, et al : Molecular determinants for the tissue specificity of SERMs. Science 295 : 2465─2468, 2002

17）Kearbey JD, et al : Effects of selective androgen receptor modulator（SARM） treatment in osteopenic female rats. Pharm Res 26 : 2471─2477, 2009

18）Vajda EG, et al : Combination treatment with a selective androgen receptor modulator（SARM） and a bisphosphonate has additive effects in osteopenic female rats. J Bone Miner Res 24 : 231─240, 2009

19）Furuya K, et al : Mechanism of the tissue-specific action of the selective androgen receptor modulator S-101479. Biol Pharm Bull 36 : 442─451, 2013

20）Akita K, et al : A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. Eur J Pharmacol 720 : 107─114, 2013

21）Dalton JT, et al : The selective androgen receptor modulator GTx-024（enobosarm） improves lean body mass and physical function in healthy elderly men and postmenopausal women : results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2 : 153─161, 2011

22）Dobs A, et al : Effects of enobosarm on muscle wasting and physical function in patients with cancer : a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14 : 335─345, 2013